Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dr-Rahul-Purwar"

2 News Found

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
News | October 16, 2023

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT
News | November 20, 2021

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT

ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.

Latest Stories

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Dr. Umesh N Jindal Director, Jindal IVF
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India

Packaging

A PHP Error was encountered

Severity: Core Warning

Message: PHP Startup: Unable to load dynamic library 'newrelic.so' (tried: /usr/lib64/php/modules/newrelic.so (/usr/lib64/php/modules/newrelic.so: cannot open shared object file: No such file or directory), /usr/lib64/php/modules/newrelic.so.so (/usr/lib64/php/modules/newrelic.so.so: cannot open shared object file: No such file or directory))

Filename: Unknown

Line Number: 0

Backtrace: